Platinum-based chemotherapy in metastatic breast cancer : current status
Decatris, M. P., Sundar, S., & O'Byrne, Kenneth J. (2004) Platinum-based chemotherapy in metastatic breast cancer : current status. Cancer Treatment Reviews, 30(1), pp. 53-81.
Cisplatin and carboplatin are active in previously untreated patients with metastatic breast cancer (MBC) with mean response rates (RRs) of 50 and 32%, respectively. In pretreated patients the RR to cisplatin/carboplatin monotherapy declines markedly to <10%. Cisplatin and carboplatin have been combined with many other cytotoxics. In first-line setting high activity has been observed in combination with taxanes or vinorelbine (RRs consistently ∼60%). It appears that these newer combinations are superior to older regimens with etoposide (RRs 30 to 50%) or 5-fluorouracil (RRs 40 to 60%). Cisplatin-/carboplatin-based regimens with infusional 5-FU and epirubicin/paclitaxel/vinorelbine achieve high RRs of around 60 to 80%. However these regimens are difficult to administer in all patients because they require central venous access for continuous 5-FU infusion. In pretreated MBC the combinations of cisplatin-taxane/vinorelbine/gemcitabine or carboplatin-docetaxel/vinorelbine yield RRs of 40 to 50%, which are higher than those achieved with platinum-etoposide/5-FU. In locally advanced disease cisplatin-based regimens achieve very high RRs (>80%). This would suggest that in chemotherapy-naïve patients platinum-based therapy might have an important role to play. Additionally the synergy demonstrated between platinum compounds, taxanes and herceptin, in preclinical and clinical studies is of immense importance and the results of the two ongoing Breast Cancer International Research Group randomized phase III studies are eagerly awaited. These studies may help clarify the role of platinum compounds in the treatment of metastatic and possibly early breast cancer. © 2003 Elsevier Ltd. All rights reserved.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||Breast cancer, Carboplatin, Chemotherapy, Cisplatin, Herceptin, Oxaliplatin, Platinum, corticosteroid, cyclophosphamide, docetaxel, doxorubicin, epirubicin, etoposide, fluorouracil, folinic acid, furosemide, gemcitabine, granisetron, granulocyte colony stimulating factor, lonidamine, magnesium ion, mannitol, methotrexate, mitomycin C, navelbine, ondansetron, paclitaxel, platinum derivative, prednisolone, taxane derivative, thiotepa, trastuzumab, unindexed drug, vinblastine, alopecia, anemia, antineoplastic activity, area under the curve, blood toxicity, bone marrow suppression, bone marrow toxicity, brain disease, breast metastasis, cancer combination chemotherapy, cancer regression, central venous catheterization, chemotherapy induced emesis, clinical trial, continuous infusion, drug clearance, drug excretion, drug half life, drug hypersensitivity, drug potentiation, drug response, drug structure, dysphagia, dyspnea, early cancer, hearing loss, human, hypomagnesemia, larynx disorder, leukopenia, meta analysis, monotherapy, myalgia, nausea and vomiting, nephrotoxicity, neurotoxicity, neutropenia, ototoxicity, peripheral neuropathy, pharynx disease, review, seizure, sensory neuropathy, sepsis, thrombocytopenia, tinnitus, Adult, Age Distribution, Aged, Antineoplastic Combined Chemotherapy Protocols, Biopsy, Needle, Breast Neoplasms, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Immunohistochemistry, Maximum Tolerated Dose, Middle Aged, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Randomized Controlled Trials, Risk Assessment, Survival Analysis, Treatment Outcome|
|Divisions:||Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 2004 W.B. Saunders Co. Ltd.|
|Deposited On:||02 Dec 2013 02:18|
|Last Modified:||07 Jan 2014 04:43|
Repository Staff Only: item control page